Inhibition of FACT using the small molecule curaxin compound CBL0137 results in a decrease of MYCN and SSRP1 expression, as well as a markedly reduced NB tumor initiation and progression in the TH-MYCN mice especially when combined with standard chemotherapy (143). This evidence concerns the gene MYCN and neoplasm.